Lutathera Just Got Its First Copycat. Radioligand Therapy Will Never Be the Same.
The FDA just approved the first-ever generic radioligand drug, a copycat of Novartis' blockbuster Lutathera. It's a regulatory first that could crack open pricing and competition in one of oncology's most complex (and expensive) drug categories.
The Era of Knockoff Nuclear Medicine Has Arrived
For years, radioligand therapy has enjoyed a kind of moat that most drugs can only dream of. The manufacturing is absurdly complex, the ingredients are literally radioactive, and the supply chain has to move faster than a pizza delivery because the medicine is actively decaying. Making a generic version? Good luck.
Well, someone just did it.
The FDA has cleared Bexlutry, a copycat of Novartis' Lutathera, making it the first-ever generic radioligand drug to receive full U.S. approval. The manufacturer, Curium, pulled off something the industry assumed was years away: proving that even the most complex radiopharmaceuticals can be copied, approved, and brought to market.
This isn't just a new drug approval. It's a regulatory earthquake.
What Lutathera Does (and Why It Matters)
Lutathera (lutetium Lu 177 dotatate) treats a specific type of cancer called gastroenteropancreatic neuroendocrine tumors, or GEP-NETs. These are rare tumors that form in the digestive system and often express a protein called a somatostatin receptor on their surface. Think of that receptor as a homing beacon. Lutathera locks onto it and delivers a targeted dose of radiation directly to the tumor, like a guided missile instead of carpet bombing.
The drug earned its FDA approval back in 2018 based on the NETTER-1 trial, which enrolled about 229 patients whose tumors had stopped responding to standard treatment. It became a cornerstone therapy for these patients, and Novartis has since built an entire radioligand empire around it.
How big is that empire? Lutathera pulled in roughly $724 million in sales in 2024 alone. Combined with Pluvicto (its prostate cancer cousin), Novartis has turned radioligand therapy into one of the hottest segments in oncology. A four-dose course of Lutathera runs about $244,000 at U.S. wholesale prices.
Those price tags help explain why someone wanted to make a cheaper version.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
How Curium Cracked the Code
Curium got Bexlutry approved through the 505(b)(2) pathway, a regulatory route that lets a company lean on the existing safety and efficacy data from the original drug rather than running an entirely new set of clinical trials from scratch. It's a hybrid: not a full generic application, but not a brand-new drug either. Think of it like building a house using someone else's blueprints while adding your own foundation work.
Meanwhile, another company called Lantheus has its own Lutathera copycat, PNT2003, which received tentative approval through the more traditional ANDA generic pathway. But "tentative" is the key word there. That product is still blocked by patent and exclusivity protections and hasn't actually reached the market.
Curium beat them to the finish line.
The distinction matters because it shows there are now multiple regulatory roads leading to generic radioligand drugs. The FDA doesn't have a special statute for radioligand generics; instead, it's handling them case by case within existing frameworks. Product-specific guidance, tailored evidence packages, and alternative bioequivalence approaches are all on the table. The playbook is being written in real time.
Why This Is Harder Than Making a Generic Advil
If you're wondering why it took this long for someone to copy a drug that's been on the market since 2018, the answer comes down to physics and logistics.
Radiopharmaceuticals aren't like pills sitting in a bottle on a pharmacy shelf. Lutetium-177 decays constantly. You can't manufacture a batch on Monday and ship it whenever you feel like it. Production and delivery have to be synchronized in a just-in-time model, almost like delivering fresh sushi instead of canned tuna.
The manufacturing facilities need hot cells (heavily shielded rooms for handling radioactive material), specialized waste disposal systems, radiation monitoring equipment, and staff trained in both pharmaceutical quality and nuclear safety. Only a handful of nuclear reactors worldwide produce Lu-177 in the first place, so any disruption at the source can ripple through the entire supply chain.
Then there's the last mile. Hospitals and nuclear pharmacies on the receiving end also need the infrastructure to store, prepare, and safely dispense radioactive drugs. It's a bottleneck at every stage.
All of this means that generic radioligand competition won't look like the wave of cheap copies that flood the market when, say, a cholesterol pill loses its patent. The barriers are real, and they're structural.
What This Means for Novartis
Novartis isn't panicking just yet, but it should be paying close attention. The company has invested heavily in U.S. manufacturing capacity for its radioligand portfolio, and analysts generally view its scale, supply chain control, and pipeline breadth as significant competitive advantages.
But the math is straightforward. If generic alternatives can offer the same therapy at a lower price, payers will notice. Hospitals will notice. Novartis reported $207 million in Lutathera sales in just the first half of 2025, showing the franchise is still growing. The question is whether that growth curve bends once competitors actually start shipping product.
Patent protection for Lutathera spans a wide range, with coverage extending from as early as 2025 to as late as 2039 depending on the specific patents involved. Industry estimates have pegged realistic generic entry around 2026 to 2027, which lines up almost perfectly with Bexlutry's arrival.
The Bigger Picture
Zoom out and the implications get even more interesting. Novartis isn't the only company betting big on radioligand therapy. Dozens of clinical trials are underway across prostate cancer, breast cancer, neuroendocrine tumors, and other solid tumors.
Every company building a radioligand drug just got a reality check: your product may eventually face generic competition, even if it requires nuclear reactors and hot cells to manufacture. The complexity tax that once protected pricing power has a crack in it now.
For patients, that's potentially great news. More competition could mean better access and lower costs for therapies that were previously out of reach for many. For investors, the calculus just shifted. First-mover advantage in radioligand therapy is still valuable, but it's no longer a permanent fortress.
The FDA just proved that even nuclear medicine has a generic future. The only question is how fast it arrives.
Deals & M&A4 min read
Lilly's $2.9 Billion Bet on a Company You've Never Heard Of
Eli Lilly is paying up to $2.875 billion for a four-year-old startup with a Phase 1 drug and $121 million in venture funding. It sounds insane, but Lilly's 12th acquisition of 2026 reveals a deliberate strategy to spend its GLP-1 fortune before competitors catch up.
